TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Phase 1 dose escalation (3+3): dose 1 (1 × 10\^6 cells/kg), dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2: dose of RP2D.

Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.

Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.